
2008-11-05
Small
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Pharmaceuticals and Chemical IntermediatesFine Chemical ManufacturingChemical Engineering Technology Research and Development and Process Package
Country / Region:
China
Company Type:
OtherPublicly listed companyListed companySpecialized refined distinctive and innovative enterprises
Registered Capital:
RMB 51.325 million
Liaoning Novino Pharmaceutical Co., Ltd. (formerly Liaoning Novino Pharmaceutical Co., Ltd.) is a national high-tech enterprise specializing in the research and development, manufacturing, and marketing of chemical pharmaceuticals. The company focuses on the R&D and industrialization of generic chemical drugs targeting anti-infective, respiratory, digestive, and cardiovascular-cerebrovascular indications. Its core business encompasses GMP-compliant manufacturing of tablets, hard capsules, granules, and active pharmaceutical ingredients (APIs)—including ambroxol hydrochloride, cetirizine hydrochloride, and amoxicillin–clavulanate potassium. Key products include ambroxol hydrochloride oral solution, cetirizine hydrochloride tablets, and amoxicillin–clavulanate potassium dispersible tablets—all included in the 2024 National Medical Insurance Catalog—and distributed across hospitals and retail outlets in over 30 provinces and municipalities nationwide. The company possesses robust R&D and technology transfer capabilities, holding 12 valid invention patents (granted primarily between 2019 and 2024), covering critical areas such as polymorph control and preparation processes. It participated in drafting the group standard “Technical Requirements for Consistency Evaluation of Oral Solid Chemical Drug Preparations” (T/CNPPA 3012–2022) and was recognized as a “Specialized, Refined, Distinctive, and Innovative” small- and medium-sized enterprise by Liaoning Province (2023). In terms of qualifications, the company holds the “Pharmaceutical Production License” (Liao 20160019) issued by the Liaoning Provincial Drug Administration, most recently renewed in August 2024; passed certification under the revised “Good Manufacturing Practice for Pharmaceutical Products” (2010 edition) in 2021; completed intelligent transformation of its API production workshop; and underwent an FDA pre-approval on-site inspection in 2022 (a stage-based compliance assessment). The company has ranked among the Top 100 Chinese Chemical Pharmaceutical Formulation Enterprises for three consecutive years. Collaboration opportunities include joint development of generic drugs, technical support for consistency evaluation, customized API supply, co-building regional market distribution channels, and collaborative optimization of GMP compliance systems.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































